GSTM1 and colorectal cancer: FIT results discriminated low‐risk groups with a 0 per cent colorectal cancer detection rate (fHb below 4·0 μg Hb/g faeces) and 2·1 per cent detection rate (fHb between 4·0 and 9·9 μg Hb/g faeces), from high‐risk patients with a colorectal cancer detection rate of 34·6 per cent (fHb 150 μg Hb/g faeces or more) (Table 4).